Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: The Maastricht study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 951-960

  Spauwen, P J J ^a,b   Van Eupen, M G A ^a,c   Kohler S ^a,b   Stehouwer, C D A ^a,c   Verhey, F R J ^a,b   Van Der Kallen, C J H ^a,c   Sep, S J S ^a,c   Koster, A ^b   Schaper, N C ^a,c   Dagnelie, P C ^b,c   Schalkwijk, C G ^a,c   Schram, M T ^a,c   Van Boxtel, M P J ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PENTOSIDINE; PLASMA PROTEIN;

ADULT; ARTICLE; AUTOFLUORESCENCE; BLOOD LEVEL; CARDIOVASCULAR RISK; COGNITION; COGNITION ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPONSE INHIBITION; SKIN AUTOFLUORESCENCE; TISSUE LEVEL; VERBAL MEMORY; WORD RECOGNITION; AGED; CLINICAL TRIAL; INHIBITION (PSYCHOLOGY); INTELLIGENCE TEST; MEMORY; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; RECALL;

AGED; COGNITION; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INHIBITION (PSYCHOLOGY); INTELLIGENCE TESTS; MALE; MEMORY; MENTAL RECALL; MIDDLE AGED;

EID: 84924943314     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2754     Document Type: Article

References (47)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63-75.e2.
2. LaFerla FM, Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170-176.
3. Daviglus ML, Bell CC, Berrettini W, et al. NIH state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements. 2010;27:1-30.
4. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-828.
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-234.
6. Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci. 2012;317:1-5.
7. Schalkwijk CG, Brouwers O, Stehouwer CD. Modulation of insulin action by advanced glycation endproducts: a new player in the field. Horm Metab Res. 2008;40:614-619.
8. Li XH, Du LL, Cheng XS, et al. Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis. 2013;4:e673.
9. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis. 2010;37:67-76.
10. Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis. 2010;22:849-859.
11. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.
12. Moran C, Munch G, Forbes JM, et al. Type 2 diabetes mellitus, skin autofluorescence and brain atrophy [published online July 22, 2014]. Diabetes. doi:10.2337/db14-0506.
13. Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 1998;101:1142-1147.
14. Hanssen NM, Engelen L, Ferreira I, et al. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)-lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab. 2013;98:E1369-E1373.
15. Yaffe K, Lindquist K, Schwartz AV, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology. 2011;77:1351-1356.
16. Chen G, Cai L, Chen B, et al. Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care. 2011;34:2586-2590.
17. Schram MT, Sep SJ, van der Kallen CJ, et al. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. Eur J Epidemiol. 2014;29:439-451.
18. Koetsier M, Nur E, Chunmao H, et al. Skin color independent assessment of aging using skin autofluorescence. Opt Express. 2010;18:14416-14429.
19. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:610-614.
20. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29:494-511.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc. 2005;11:290-302.
23. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment. 2006;13:62-79.
24. van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006;28:998-1009.
25. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
26. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Published January 14, 2006. http://www.who.int/diabetes/publications/Definition anddiagnosis of diabetes-new.pdf. 2006.
27. De Bie SE. Standaardvragen 1987: Voorstellen voor uniformering van vraagstellingen naar achtergrondkenmerken en interviews [Standard questions 1987: Proposal for uniformization of questions regarding background variables and interviews]. Leiden, The Netherlands: Leiden University Press. 1987.
28. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33;quiz 34-57.
29. Gainotti G, Quaranta D, Vita MG, Marra C. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis. 2014;38:481-495.
30. Spauwen PJ, Köhler S, Verhey FR, Stehouwer CD, van Boxtel MP. Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study. Diabetes Care. 2013;36:1554-1561.
31. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care. 2009;12:15-21.
32. Yoon DH, Choi SH, Yu JH, Ha JH, Ryu SH, Park DH. The relationship between visceral adiposity and cognitive performance in older adults. Age Ageing. 2012;41:456-461.
33. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271:9982-9986.
34. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61:705-714.
35. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA. 1997;94:13915-13920.
36. Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Arch Intern Med. 2008;168:1165-1173.
37. Kalousová M, Zima T, Popov P, et al. Advanced glycation endproducts in patients with chronic alcohol misuse. Alcohol Alcohol. 2004;39:316-320.
38. Xu G, Liu X, Yin Q, Zhu W, Zhang R, Fan X. Alcohol consumption and transition of mild cognitive impairment to dementia. Psychiatry Clin Neurosci. 2009;63:43-49.
39. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004;64:459-470.
40. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26:1636-1641.
41. Tiemeier H, Breteler MM, van Popele NM, Hofman A, Witteman JC. Late-life depression is associated with arterial stiffness: a population-based study. J Am Geriatr Soc. 2003;51:1105-1110.
42. Köhler S, van Boxtel MP, van Os J, et al. Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc. 2010;58:873-879.
43. Semba RD, Ferrucci L, Fink JC, et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis. 2009;53:51-58.
44. Buchman AS, Tanne D, Boyle PA, Shah RC, Leurgans SE, Bennett DA. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology. 2009;73:920-927.
45. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ. 1994;308:1604-1608.
46. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488-495.
47. Meli M, Perier C, Ferron C, et al. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis. 2002;4:93-96.